Skip to main content
. 2021 Dec 28;6:77–81. doi: 10.1016/j.jdin.2021.12.007

Table III.

Summary of literature evaluating association of AD and COVID-19

Study Subjects (N) Results Conclusions
Wu et al5 39,417 AD patients with matched controls (US)
  • 1.

    IRR of COVID-19 in AD patients = 1.18 (1.11-1.53, P < .0001) or 1.31 (1.11-1.53, P = .001), depending on sensitivity analysis

  • 2.

    IRR of COVID-19 in AD patients on dupilumab = 0.66 (0.52-0.83, P < .0001)

 AD was associated with increased risk of COVID-19 infection.
Dupilumab was associated with decreased risk of COVID-19 infection in AD patients.
Nguyen et al6 5387 AD patients (US) COVID-19 infection rate in AD vs non-AD patients = 2.95% vs 3.66%, P = .0063 AD was associated with a decreased rate of COVID-19 infection.
Kridin et al4 238 AD patients on dupilumab (Israel)
  • 1.

    HR of COVID-19, dupilumab vs systemic corticosteroids = 1.13 (0.61-2.09, P = .699)

  • 2.

    HR of COVID-19, dupilumab vs phototherapy = 0.80 (0.42-1.53, P = .500)

  • 3.

    HR of COVID-19, dupilumab vs azathioprine and MMF = 1.10 (0.45-2.65, P = .840)

 No difference in COVID-19 infection rates in AD patients on dupilumab vs systemic corticosteroids, phototherapy, or azathioprine and MMF.
Patrick et al7 18,360 AD patients (US) OR of COVID-19 in AD patients = 1.48 (1.06-2.06, P = .020) AD was associated with increased odds of COVID-19 infection.
Current study 11,752 AD patients with matched controls (US) OR of COVID-19 in AD patients = 1.29 (1.15-1.44, P < .001) AD was associated with increased odds of COVID-19 infection.

AD, Atopic dermatitis; IRR, incidence rate ratio; HR, hazard ratio; MMF, mycophenolate mofetil; OR, odds ratio.